(b)(4) and tutogen medical (b)(4), a wholly owned subsidiary of (b)(4) received a complaint on 05/05/2015 reporting a tutomesh graft was utilized in a thoracic wall replacement procedure and removal of 4 ribs on (b)(6) 2015.The graft was implanted with tension onto surrounding ribs.Approximately two weeks post operatively, the patient underwent revision of a hematoma.During the procedure, it was noted that the graft had ruptured.The patient underwent a revision procedure on (b)(6) 2015.The complaint notification indicated the patient's medical history was significant for sarcomatoid differentiated pulmonary carcinoma with no irradiation therapy initiated.
|
Method: graft was not returned to rti for evaluation, therefore a re-review was performed of the manufacturing records, sterilization run reports, environmental monitoring results, quality control/assurance reviews adn release, and the complaint database for related complaints associated with the lot.Results: no deviations were noted during processing for lot# nz217160410.The graft underwent a validated sterilization methodology; tutoplast which includes terminal sterilization by gamma irradiation after packaging.To date, rti has distributed 1 xenograft from the lot.There is 1 related complaint associated with the physician, this surgery type, but not the same lot.Environmental data and records generated during and around the time of processing for lot # nz217160410 were acceptable.Conclusion: given that no deviations were noted in record re-review, graft id (b)(4) was manufactured to specification prior to distribution; and the complex nature of the surgical procedure, it is more plausible that the patient's surgical outcome was associated with a source or event extrinsic to the xenograft implant.
|